+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07296484

Randomized Trial of Clofutriben Versus Placebo for Type 2 Diabetes Patients with Elevated Cortisol

Led by Sparrow Pharmaceuticals · Updated on 2026-10-06

1500

Participants Needed

61

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

This research evaluates the drug clofutriben in patients with type 2 diabetes who have elevated cortisol levels. The study aims to understand how different doses of clofutriben affect blood sugar control and to find one or more doses suitable for further testing. It is a two-part, multicenter, randomized, double-blind trial designed to assess clofutribens impact compared to a placebo. The trial has two parts. Part 1 is a screening phase lasting about 5 to 9 weeks, including initial eligibility assessment, a dexamethasone suppression test, and further evaluations. Participants who qualify then enter Part 2, where they are randomly assigned to receive one of four doses of clofutriben or a placebo, taken daily by mouth for 24 weeks. After treatment, there is a follow-up phone call 4 weeks later. Participants will undergo various assessments including blood tests for cortisol and glycated hemoglobin HbA1c to measure effects on cortisol levels and blood sugar control. The main outcomes include changes in HbA1c and cortisol levels after 24 weeks of treatment. Safety and other blood sugar measures will also be monitored. The total involvement may last several months including screening, treatment, and follow-up.

CONDITIONS

Brief Title

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here